GW Pharmaceuticals PLC- (NASDAQ:GWPH) Rating Increased to Buy at BidaskClub

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, December 22nd.

GWPH has been the subject of several other research reports. Cantor Fitzgerald set a $208.00 price target on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Monday, December 4th. Bank of America dropped their target price on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a research report on Tuesday, November 14th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $124.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Friday, October 6th. ValuEngine upgraded shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Leerink Swann restated an “outperform” rating and set a $153.00 price objective (down from $160.00) on shares of GW Pharmaceuticals PLC- in a research report on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $148.78.

Shares of GW Pharmaceuticals PLC- (NASDAQ GWPH) traded down $0.56 on Friday, reaching $131.97. 189,050 shares of the company were exchanged, compared to its average volume of 428,093. GW Pharmaceuticals PLC- has a one year low of $92.65 and a one year high of $140.52. The company has a quick ratio of 7.47, a current ratio of 7.59 and a debt-to-equity ratio of 0.02. The company has a market cap of $3,350.00, a price-to-earnings ratio of -18.72 and a beta of 2.65.

A number of hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in GW Pharmaceuticals PLC- by 2.6% during the third quarter. Janus Henderson Group PLC now owns 717,729 shares of the biopharmaceutical company’s stock worth $72,842,000 after buying an additional 18,194 shares during the period. Capital World Investors boosted its stake in GW Pharmaceuticals PLC- by 6.3% during the second quarter. Capital World Investors now owns 675,800 shares of the biopharmaceutical company’s stock worth $67,749,000 after buying an additional 40,000 shares during the period. Jennison Associates LLC boosted its stake in GW Pharmaceuticals PLC- by 0.4% during the third quarter. Jennison Associates LLC now owns 492,480 shares of the biopharmaceutical company’s stock worth $49,982,000 after buying an additional 1,759 shares during the period. Redmile Group LLC boosted its stake in GW Pharmaceuticals PLC- by 33.8% during the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock worth $44,605,000 after buying an additional 112,392 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in shares of GW Pharmaceuticals PLC- by 102.6% during the third quarter. Pictet Asset Management Ltd. now owns 355,263 shares of the biopharmaceutical company’s stock worth $36,056,000 after purchasing an additional 179,911 shares in the last quarter. 74.57% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/gw-pharmaceuticals-plc-gwph-rating-increased-to-buy-at-bidaskclub.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply